Conversely, mutations in genes such as FLT3, IDH1/IDH2, RUNX1, and TP53 are not only associated with distinct AML subtypes but also correlate with adverse prognosis and influence patient responsiveness to therapy [7,8,9,10]. Here, FLT3 is linked to acute myeloid leukemia.